

**To:** Giroir, Brett (HHS/OASH) (b) (6)>  
**Cc:** Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>  
**Subject:** RE: COVID and Chloroquine  
**Importance:** High

Brett:

Thanks for the note. I will run this by the people in our Program and get back to you.

Best,

Tony

Cristina:

Are we or anyone else doing anything with clinical trials and chloroquine for COVID-19? Please respond directly to ADM Giroir.

Thanks,

Tony

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Giroir, Brett (HHS/OASH) (b) (6)>  
**Sent:** Saturday, February 29, 2020 9:31 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** COVID and Chloroquine

You know the old data and the new data. New in vitro look promising.  
Do you have good visibility on the trials being conducted? Or is NIH running any of these?

Your time is precious, so 10 word response sufficient.